FRONTIERS IN BIOSCIENCE PRESENTS

THE SPECIAL ISSUE


SIGNATURE OF NORMAL AND CANCER CELLS:
MOLECULAR TARGETS FOR CANCER THERAPY

Managing Editor: Subrata Haldar

  

 
TABLE OF CONTENTS

Function and dysfunction of the human oncoprotein MDM2
Swati Palit Deb

[Frontiers in Bioscience 7, d235-243, January 1, 2002]

Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and the therapeutic uses of tamoxifen
Monica M. Montano, Nicole R. Bianco, Huayun Deng, Bryan M. Wittmann, Laura C. Chaplin and Benita S. Katzenellenbogen

[Frontiers in Bioscience 10, 1440-1461 May 1, 2005]

Tumor antigen targets and tumor immunotherapy
R. Allan Mufson

[Frontiers in Bioscience 11, 337-343, January 1, 2006]

Posttranslational modifications of Bcl2 family members-a potential therapeutic target for human malignancy
Aruna Basu, Garrett DuBois and Subrata Haldar

[Frontiers in Bioscience 11, 1508-1521, May 1, 2006]

APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy
Octavian Bucur, Subrata Ray, Maria Cristina Bucur, and Alexandru Almasan

[Frontiers in Bioscience 11, 1549-1568, May 1, 2006]

Signature of mitochondria of steroidal hormones-dependent normal and cancer cells: potential molecular targets for cancer therapy
Deodutta Roy, Quentin Felty, Satya Narayan and Prasanna Jayakar

[Frontiers in Bioscience 12, 154-173, January 1, 2007]

Chromosomal deletions in bladder cancer: shutting down pathways
Reimar Abraham, Francesco Pagano, Leonard G. Gomella and Raffaele Baffa

[Frontiers in Bioscience 12, 826-838, January 1, 2007]